Added to YB: 2025-09-04
Pitch date: 2025-07-17
IKNA [bullish]
Ikena Oncology, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance.
Market Cap
$69.0M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.58
P/E
-2.24
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Show full summary:
Ikena Oncology, Inc - $IKNA
IKNA: Reverse merger w/ Imagene (OX40 atopic dermatitis) + CVR for MEK inhibitor. PIPE at $2.42 vs current $1.30 (85% premium) from top biotech funds. IMG-007 entering 220pt P2b trial, data Q4 2026. $15B+ AD market; OX40 validated by AMGN/SNY P3s. Trading at ~neutral EV w/ $175M cash at close.
Read full article (6 min)